▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3129 by analyst upside · 2026-09-27
MASS
908 Devices Inc.
Healthcare · Market Cap $473M · P/E 0x
ANALYST PRICE TARGET
+16.9%
implied upside to consensus target
Current Price $11.44
Consensus Target $13.38
Bull Target $14.0
Bear Target $12.0
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $5.03
52-Week High $11.71
YTD Return +124.8%
FUNDAMENTALS
Market Cap $473M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.93
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $61M
Profit Margin -57.0%
52-WEEK RANGE
52-Week Low $5.03
52-Week High $11.71
Current Price $11.44
Bear Target $12.0
Bull Target $14.0
● Now $11.44 ● Target $13.38
TRADING DATA
Avg Volume 383K
YTD Return +124.8%
Analyst Count 4
Consensus Buy
Upside to Target +16.9%
Last Updated 2026-09-27

ANALYST SUMMARY

908 Devices Inc. (MASS) is currently trading at $11.44 with a Wall Street consensus price target of $13.38, implying potential upside of 16.9% over the next 12 months. 4 analysts currently cover MASS, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $12.0.

MASS operates in the Healthcare sector with a market capitalisation of $473M. The stock is up 124.8% year-to-date and is currently trading near the upper end of its 52-week range of $5.03 – $11.71.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for MASS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity ● Initiated
Buy 2026-09-10 Building track record
Stifel - Reiterated
Buy → Buy 2026-08-12 Building track record
Roth Capital - Reiterated
Buy → Buy 2026-08-12 Building track record
Roth Capital ● Initiated
Buy 2026-07-29 Building track record
Leerink Partners ↑ Upgrade
Market Perform → Outperform 2025-08-05 29% win rate (7 calls)
Stephens & Co. reit
Overweight → Overweight 2025-01-15 Building track record
Stifel - Reiterated
Buy → Buy 2024-11-13 Building track record
Leerink Partners ↓ Downgrade
Outperform → Market Perform 2024-11-13 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
66
out of 100
Coverage depth
12/30
Consensus clarity
27/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →